Top

Published in:

01-03-2010

Decreased p21 Expression in HPV-18 Positive Cervical Carcinomas

Authors: Lee-Wen Huang, Kok-Min Seow, Chin-Cheng Lee, Yu-Hung Lin, Hun-Shan Pan, Heng-Ju Chen

Published in: Pathology & Oncology Research | Issue 1/2010

Abstract

The aim of this study was to investigate the relationship between different human papillomaviruse (HPV) genotypes and the expression of p53, p21 and p27 in cervical carcinomas. A total of 103 cases of cervical carcinomas were assayed for expression of p53, p21 and p27 by immunohistochemistry. HPV typing was carried out by two polymerase chain reaction-based methods. Overall, HPV prevalence was 97.1% among the cervical carcinomas in this study. HPV-16 was detected in 66% of the tumors, HPV-18 in 7.8%, HPV-16/18 in 7.8% and other HPV types in 15.5%. The expression of p53 and p27 was not related to HPV genotype. However, in the HPV-18 positive cervical carcinomas, expression of p21 was significantly decreased or completely absent (P = 0.019). Our results indicated that down-regulation of p21 was strongly associated with HPV-18 positive cervical carcinomas. The significantly lower expression of p21 protein in HPV-18 positive samples compared to HPV-18 negative cervical carcinomas supports the hypothesis that inactivation and degradation of p21 proteins by HPV-18 E7 may play an important role in the carcinogenesis of HPV-18 positive cervical neoplasia.

Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19CrossRefPubMed

Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905–3910PubMed

Galloway DA, McDougall JK (1996) The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 7:309–315CrossRefPubMed

zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698CrossRefPubMed

Chen YQ, Cipriano SC, Arenkiel JM, Miller FR (1995) Tumor suppression by p21^WAF1. Cancer Res 55:4536–4539PubMed

Costa MJ, Hansen CL, Walls JE, Scudder SA (1999) Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21^WAF1/CIP1 predicts survival and good response to platinin-based chemotherapy. Hum Pathol 30:640–647CrossRefPubMed

Ropponen KM, Kellokoski JK, Lipponen PK, Pietilainen T, Eskelinen MJ, Alhava EM, Kosma VM (1999) p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br J Cancer 81:133–140CrossRefPubMed

Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M (1997) Loss of p21 ^WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 75:1617–1620PubMed

Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama KI (1996) Mice lacking p27^Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707–720CrossRefPubMed

10.

Troncone G, Vetrani A, Rosa GD, Gerbasio D, Palombini L (1999) Cyclin dependent kinase inhibitor p27^Kip1 expression in normal and neoplastic cervical epithelium. J Clin Pathol 52:880–887CrossRefPubMed

11.

Kim YT, Choi EK, Cho NH, Ko JH, Yang WI, Kim JW, Lee SH (2000) Expression of cyclin E and p27^KIP1 in cervical carcinoma. Cancer Lett 153:41–50CrossRef

12.

Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331CrossRefPubMed

13.

El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppressor. Cell 75:817–825CrossRefPubMed

14.

Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53CrossRefPubMed

15.

Woodman CB, Collins S, Rollason TP, Winter H, Bailey A, Yates M et al (2003) Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 361:40–43CrossRefPubMed

16.

Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M et al (1999) Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 91:954–960CrossRefPubMed

17.

Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A (1996) Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 69:364–368CrossRefPubMed

18.

Huang LW, Chao SL, Hwang JL, Chou YY (2002) Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol Oncol 85:524–528CrossRefPubMed

19.

Huang LW, Chou YY, Chao SL, Chen TJ, Lee TT (2001) p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol. 83:348–354CrossRefPubMed

20.

Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136CrossRefPubMed

21.

Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11:2090–2100CrossRefPubMed

22.

Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P (1996) Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene. 13:2323–2330PubMed

23.

Huang LW, Chao SL, Chen PH, Chou HP (2004) Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol 29:271–276CrossRefPubMed

24.

Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ (1992) Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 79:328–337CrossRefPubMed

25.

Lie AK, Skarsvag S, Skomedal H, Haugen OA, Holm R (1999) Expression of p53, MDM2, and p21 proteins in high-grade cervical intraepithelial neoplasia and relationship to human papillomavirus infection. Int J Gynecol Pathol 18:5–11PubMedCrossRef

26.

Cavuslu S, Goodlad J, Hobbs C, Connor AM, Raju KS, Best JM, Cason J (1997) Relationship between human papillomavirus infection and overexpression of p53 protein in cervical carcinomas and lymph node metastases. J Med Virol 53:111–117CrossRefPubMed

27.

Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D (1994) Induction of WAF1/CIP1 by a p53-independent Pathway. Cancer Res 54:3391–3395PubMed

28.

Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ (1995) p53-independent expression of p21^Cip1 in muscle and other terminally differentiating cells. Science 267:1024–1027CrossRefPubMed

29.

Jones DL, Alani RM, Munger K (1997) The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 11:2101–2111CrossRefPubMed

30.

Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, Aster JC, Krishna S, Metzger D, Chambon P, Miele L, Aguet M, Radtke F, Dotto GP (2001) Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 20:3427–3436CrossRefPubMed

31.

Werness BA, Wang HQ, Chance J, Goldstein DJ (1997) p53-independent expression of p21waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix. Mod Pathol 10:578–584PubMed

32.

Nadal A, Jares P, Cazorla M, Fernández PL, Sanjuan X, Hernandez L, Pinyol M, Aldea M, Mallofré C, Muntané J, Traserra J, Campo E, Cardesa A (1997) p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 183:156–163CrossRefPubMed

33.

Burger RA, Monk BJ, Kurosaki T, Anton-Culver H, Vasilev SA, Berman ML, Wilczynski SP (1996) Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 88:1361–1368CrossRefPubMed

Title: Decreased p21 Expression in HPV-18 Positive Cervical Carcinomas
Authors: Lee-Wen Huang
Kok-Min Seow
Chin-Cheng Lee
Yu-Hung Lin
Hun-Shan Pan
Heng-Ju Chen
Publication date: 01-03-2010
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-009-9191-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

HER2/neu Expression: A Predictor for Differentiation and Survival in Children With Wilms Tumor

Stereologic Analysis of Tissue Compartments of Gunshot-injured and Blunt-injured Spleen

Changes of AXIN-1 and Beta-Catenin in Neuroepithelial Brain Tumors

Expression and Methylation Pattern of p16 in Neuroblastoma Tumorigenesis

Nasal-type NK/T-cell Lymphoma with Palatal Ulcer as the Earliest Clinical Manifestation: A Case Report with Literature Review

Primary Large Cell Neuroendocrine Carcinoma of the Kidney

Keynote webinar | Spotlight on antibody–drug conjugates in cancer